Kindeva Drug Delivery


Contract development and manufacturing organization (CDMO) focused on drug–device combination products across injectable, inhalation (pulmonary and nasal) and dermal platforms. Provides formulation and device development, analytical testing, regulatory support and GMP manufacturing from early development through post-commercialization. Operates a global network of manufacturing and R&D facilities (10+ sites) with a cGMP footprint near 1,000,000 sq ft, holds ~1,300 patents, and reports large-scale commercial device production (approximately 100 million devices shipped annually).

Industries

Manufacturing
Biotech & Pharmaceuticals
Pharmaceutical and biotechnology
Pharmaceutical Manufacturing

Nr. of Employees

Very Large (1000+)

Kindeva Drug Delivery

Saint Paul, Minnesota, United States


Patents

Coating process

US-12766275-B2

View Details

Medicinal inhalers

US-12357776-B2

View Details

Applicator for applying a microneedle device to skin

US-12290672-B2

View Details

Microarray applicator

US-12246154-B2

View Details

Tiotropium formulation and inhaler

US-12220525-B2

View Details

Energy storage mechanism for an inhaler

US-12036356-B2

View Details
View All Patents

Products

Autoinjector platforms

Single- and dual-chamber autoinjector platforms designed for self-administration and combination-product integration; supported by functional performance testing and high-volume manufacturing experience for public-sector programs.

Microneedle array patch platforms

Solid-coated and hollow microneedle platforms with applicators for intradermal delivery of vaccines, peptides, proteins and other biologics.

Transdermal patch products and coating capabilities

Single- and multi-layer drug-in-adhesive patches and active gel patch formulations with GMP coating, converting and packaging services.

Inhalation device platforms and formulation services

Platform development and manufacturing for pressurized metered-dose inhalers, dry powder inhalers, soft-mist inhalers and nebulizer-compatible formulations; includes work on lower‑GWP propellants and inhalation performance testing.

Pulmonary & Nasal

Platform technologies and CDMO services for pulmonary and nasal drug delivery including pMDI, nebulizer, SMI, DPI, green propellant, and nasal sprays.

Pulmonary & nasal dry powder inhaler (DPI)

Single or multiuse devices offering stable, dispersible, and flowable powder delivery with high payload.

View All Products

Services

Formulation development, device selection, design-for-development and development-by-design approaches to prepare candidates for clinical and commercial manufacturing.

Clinical-to-commercial GMP manufacturing across injectables, inhalation and transdermal platforms with scalable batch sizes and dedicated facility capacity.

Method development and validation, stability testing, protein analytics, IVBE, CFD-based performance simulation, E&L and container closure integrity testing.

Regulatory strategy, dossier preparation (IND/NDA/ANDA/BLA/MAA), eCTD publishing, labeling support and global regulatory interactions.

Isolator-based fill finish for vials, cartridges and prefilled syringes, including integrated inspection, cleaning/depyrogenation and packaging assembly.

Post-approval regulatory support, product lifecycle extension, technical support and continuous improvement programs.

Expertise Areas

  • Aseptic fill–finish manufacturing
  • Inhalation and nasal drug delivery
  • Transdermal and intradermal delivery (microneedles)
  • Autoinjector and combination product development
  • Show More (7)

Key Technologies

  • Pressurized metered-dose inhalers (pMDI)
  • Dry powder inhalers (DPI)
  • Soft-mist inhalers (SMI)
  • Nebulizer-compatible formulation development
  • Show More (13)

News & Updates

Participation in Partnership Opportunities in Drug Delivery (PODD) 2026 to engage with industry stakeholders.

Discussion of media-fill strategy and how simulation data can be used to strengthen aseptic process control under revised Annex 1 guidance.

Analysis of manufacturing models and capacity requirements to meet increasing demand for sterile injectable therapies such as GLP-1 receptor agonists.

Collection of articles and whitepapers on aseptic fill-finish strategy, media-fill approaches and Annex 1 implications for sterile manufacturing.

Award reported for supply of autoinjectors to the U.S. Defense Logistics Agency with potential delivery of over 3 million units (reported contract value up to $226 million).

Announcement of a UK headquarters and manufacturing site focused on development and testing of next-generation low‑GWP inhalation propellants.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.